Regulation of the <i>yjjQ</i> - <i>bglJ</i> Operon, Encoding LuxR-Type Transcription Factors, and the Divergent <i>yjjP</i> Gene by H-NS and LeuO

Thomas Stratmann(University of Cologne), Karin Schnetz(University of Cologne), Srinivasan Madhusudan(Nottingham University Hospitals NHS Trust)

Journal of Bacteriology

December 1, 2007

10.1128/jb.01447-07

Cited by 52

Related Papers

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

|New England Journal of Medicine|2010|4.5k

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial

|The Lancet|2022|664

Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial

|The Lancet Oncology|2013|605

Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial

|The Lancet Oncology|2014|374

Cediranib or placebo in combination with cisplatin and gemcitabine chemotherapy for patients with advanced biliary tract cancer (ABC-03): a randomised phase 2 trial

|The Lancet Oncology|2015|282